Skip to content

Study · Not a test of the peptide alone · 2026

14 results

The role of STAT3-targeted therapy created with COLIVELIN in the cross-talk between IL6/JAK2/STAT3 and TGF-β/SMAD2/SMAD3 signaling in a hyperinflammation and ROS-induced in vitro AMD model and its effect on retinal apoptosis.

Güçlü H, Doğanlar Z, Şambel Aykutlu M, Köse G, Doğanlar O

International ophthalmology4 Jun 2026

PMID42240907 (opens in a new tab)DOI10.1007/s10792-026-04112-9 (opens in a new tab)PepBankPUB-42240907
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Colivelin.

  1. 01LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin significantly enhanced STAT3 phosphorylation.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin significantly increased STAT3 phosphorylation.

    Peptide
    Colivelin
    Outcome
    IncreaseSTAT3 phosphorylation
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    Low-dose Colivelin (1 µM) significantly enhanced STAT3 phosphorylation
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  2. 02LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin restored antioxidant GSS gene expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin restored GSS gene expression.

    Peptide
    Colivelin
    Outcome
    Direction not reportedGSS expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    restored antioxidant gene expression (GSS, CAT, SOD2)
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  3. 03LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin restored antioxidant CAT gene expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin restored CAT gene expression.

    Peptide
    Colivelin
    Outcome
    Direction not reportedCAT expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    restored antioxidant gene expression (GSS, CAT, SOD2)
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  4. 04LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin restored antioxidant SOD2 gene expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin restored SOD2 gene expression.

    Peptide
    Colivelin
    Outcome
    Direction not reportedSOD2 expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    restored antioxidant gene expression (GSS, CAT, SOD2)
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  5. 05LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin suppressed hypoxia-associated gene expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced hypoxia-associated gene expression.

    Peptide
    Colivelin
    Outcome
    DecreaseHypoxia-associated gene expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    suppressed hypoxia-associated gene expression
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  6. 06LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin substantially reduced TGF-β receptor expression at the transcriptional level.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced TGF-β receptor gene expression.

    Peptide
    Colivelin
    Outcome
    DecreaseTGF-β receptor transcription
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    and substantially reduced TGF-β receptor, SMAD2, and SMAD3 expression at both transcriptional and protein levels.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  7. 07LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin substantially reduced TGF-β receptor protein expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced TGF-β receptor protein expression.

    Peptide
    Colivelin
    Outcome
    DecreaseTGF-β receptor protein expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    and substantially reduced TGF-β receptor, SMAD2, and SMAD3 expression at both transcriptional and protein levels.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  8. 08LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin substantially reduced SMAD2 expression at the transcriptional level.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced SMAD2 gene expression.

    Peptide
    Colivelin
    Outcome
    DecreaseSMAD2 transcription
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    and substantially reduced TGF-β receptor, SMAD2, and SMAD3 expression at both transcriptional and protein levels.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  9. 09LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin substantially reduced SMAD2 protein expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced SMAD2 protein expression.

    Peptide
    Colivelin
    Outcome
    DecreaseSMAD2 protein expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    and substantially reduced TGF-β receptor, SMAD2, and SMAD3 expression at both transcriptional and protein levels.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  10. 10LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin substantially reduced SMAD3 expression at the transcriptional level.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced SMAD3 gene expression.

    Peptide
    Colivelin
    Outcome
    DecreaseSMAD3 transcription
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    and substantially reduced TGF-β receptor, SMAD2, and SMAD3 expression at both transcriptional and protein levels.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  11. 11LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, low-dose Colivelin substantially reduced SMAD3 protein expression.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin reduced SMAD3 protein expression.

    Peptide
    Colivelin
    Outcome
    DecreaseSMAD3 protein expression
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    and substantially reduced TGF-β receptor, SMAD2, and SMAD3 expression at both transcriptional and protein levels.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  12. 12LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, STAT3-driven TGF-β/SMAD2/3 suppression mediated 91-98% of Colivelin's anti-apoptotic effect at the therapeutic dose.

    In plain wordsIn cells, STAT3-driven suppression of TGF-β/SMAD2/3 signaling mediated most of Colivelin's protection against cell death.

    Peptide
    Colivelin
    Outcome
    Not applicableAnti-apoptotic effect mediation
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    Formal mediation analysis revealed that 91-98% of Colivelin's anti-apoptotic effect at the therapeutic dose was mediated through STAT3-driven suppression of TGF-β/SMAD2/3 signaling, rather than through direct STAT3 transcriptional activity on apoptotic target genes.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  13. 13LabNot a test of Colivelin aloneIn vitro (cells)Mechanism

    In the cell AMD model, high-dose Colivelin activated SMAD2/3-independent pro-apoptotic cascades.

    In plain wordsIn cells used to model eye disease, high-dose Colivelin activated signals that promote cell death independently of SMAD2/3.

    Peptide
    Colivelin
    Outcome
    IncreaseHigh-dose pro-apoptotic cascades
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    Conversely, high-dose Colivelin (10 µM) paradoxically activated SMAD2/3-independent pro-apoptotic cascades, demonstrating a dose- dependent biphasic response.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  14. 14LabNot a test of Colivelin aloneIn vitro (cells)Efficacy outcome

    In the cell AMD model, low-dose Colivelin showed superior and broader therapeutic efficacy compared with Bevacizumab across the reported signaling pathways.

    In plain wordsIn cells used to model eye disease, low-dose Colivelin showed broader and greater therapeutic efficacy than Bevacizumab.

    Peptide
    Colivelin
    Outcome
    IncreaseTherapeutic efficacy compared with Bevacizumab
    Study

    humann: not reported in source

    ARPE-19 cells exposed to lipopolysaccharide and hydrogen peroxide
    Comparator
    Bevacizumab
    Outcome group
    Receptor activity and mechanism · Eye

    Source sentences

    Summary
    Low-dose (1 µM) Colivelin demonstrated superior and broader therapeutic efficacy compared to Bevacizumab by simultaneously modulating oxidative stress, hypoxia, angiogenesis, and apoptotic signaling pathways.
    1 context sentence
    Summary · context
    An in vitro AMD model was established in ARPE-19 human RPE cells using a sublethal combination of lipopolysaccharide and hydrogen peroxide.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.